Hyperfine (HYPR) Net Income towards Common Stockholders (2021 - 2026)
Hyperfine (HYPR) posted Net Income towards Common Stockholders of -$8.6 million for Q1 2026, down 45.86% on a QoQ basis from -$5.9 million in Q4 2025, and up 8.44% year-over-year from -$8.0 million in Q1 2025.
Hyperfine (HYPR) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Hyperfine's Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$8.6 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 8.44% year-over-year to -$8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.8 million (up 13.68% YoY) and the FY2025 annual result came in at -$35.6 million, up 12.64% from the prior year.
- Net Income towards Common Stockholders was -$8.6 million for Q1 2026 at Hyperfine, down from -$5.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$5.9 million in Q4 2025 and bottomed at -$23.8 million in Q1 2022.
- A 5-year average of -$11.9 million and a median of -$10.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 205.04% — and 2023, when it surged 54.07%.
- Hyperfine's Net Income towards Common Stockholders stood at -$13.1 million in 2022, then climbed by 18.19% to -$10.7 million in 2023, then advanced by 2.75% to -$10.4 million in 2024, then jumped by 43.1% to -$5.9 million in 2025, then plunged by 45.86% to -$8.6 million in 2026.
- Business Quant data shows HYPR's Net Income towards Common Stockholders at -$8.6 million in Q1 2026, -$5.9 million in Q4 2025, and -$11.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Hyperfine | 94.51 Mn | 53.23 Mn | 1.98 Mn | -8.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.62 Mn |
| Dec 31, 2025 | -5.91 Mn |
| Sep 30, 2025 | -11.02 Mn |
| Jun 30, 2025 | -9.23 Mn |
| Mar 31, 2025 | -9.42 Mn |
| Dec 31, 2024 | -10.39 Mn |
| Sep 30, 2024 | -10.33 Mn |
| Jun 30, 2024 | -10.16 Mn |
| Mar 31, 2024 | -9.85 Mn |
| Dec 31, 2023 | -10.68 Mn |
| Sep 30, 2023 | -10.76 Mn |
| Jun 30, 2023 | -10.64 Mn |
| Mar 31, 2023 | -12.16 Mn |
| Dec 31, 2022 | -13.06 Mn |
| Sep 30, 2022 | -13.17 Mn |
| Jun 30, 2022 | -23.16 Mn |
| Mar 31, 2022 | -23.78 Mn |
| Dec 31, 2021 | -26.09 Mn |
| Sep 30, 2021 | -16.39 Mn |
| Jun 30, 2021 | -14.58 Mn |